AzTrials
AzTrials

Motor DelayNCT03770832

Wearable Sensors and Video Recordings to Monitor Motor Development

An observational study of Motor Delay and Neurodevelopmental Disorders, run by Shirley Ryan AbilityLab at 2 sites in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The objective of this study is to develop an automated, precise, quantitative assay for detecting atypical motor behavior and development in infants using data from wearable sensors and video recordings. Read more about this study

Who is it for?
Ages 0 to 24 months
How many people
150 participants
Where
2 sitesUnited States
Study dates
29 Mar 2019to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 24 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Individuals at high risk of developing motor delays <24 months of age along with infants at low risk of developing motor delays.

Who may be able to join

  • Individuals identified as potentially at risk of abnormal motor development due to a risk factor (for example, prematurity, neonatal hypoxic ischemic encephalopathy, or neonatal stroke) OR control individuals for whom normal motor development is expected.
  • Age: < 24 months of age
  • Legal guardian able and willing to give written consent and comply with study procedures.
  • In case of multiple pregnancies, only one child selected at random will participate in the research activities. Study staff will have no influence over the selection, besides any known medical condition automatically excluding the baby as listed in our exclusion criteria.

Who cannot join

  • Any open wound or skin breakdown on the limbs or upper torso.
  • Missing or incomplete limbs (such as from amputation or congenital limb defects)
  • Legal guardian unable to give written consent and comply with study procedures.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Shirley Ryan AbilityLab

    Chicago, Illinois, 60611

  • University of Illinois at Chicago

    Chicago, Illinois, 60612

Other trials in United States

About this study

Official title: Wearable Sensors and Video Recording for Children (Birth to 24 Months) to Monitor Motor Development

The objective of this study is to develop an automated, precise, quantitative assay for detecting atypical motor behavior and development in infants using data from wearable sensors and video recordings.

Keywords
Early Detection, Wearable Sensors, Computer Vision
Medical subject headings
Psychomotor Disorders, Neurodevelopmental Disorders, Developmental Disabilities

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03770832
Study groupRoleWhat they receive
Infants at Risk for Atypical Motor Development (high-risk)Not described
Infants Expected to Have Typical Motor Development (low-risk)Not described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Three month clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at the 3 month time-point.

    Measured: 3 months

  2. Six month clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at 6 month time-point.

    Measured: 6 months

  3. Prediction of neuromotor outcome using sensor and video data from 3 month time-point

    Sensitivity and specificity of algorithm (trained on sensor and video data from the 3 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])

    Measured: 3 months

  4. Prediction of neuromotor outcome using sensor and video data from 6 month time-point

    Sensitivity and specificity of algorithm (trained on sensor and video data from the 6 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])

    Measured: 6 months

Secondary outcomes (6)
  1. Prediction of neuromotor outcome using General Movements Assessment (GMA) scores

    Sensitivity and specificity of GMA scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The GMA is an observational exam where an infant's spontaneous movements are scored as atypical or normal for their age.

    Measured: 1-2 weeks, 1 month, 3 months

  2. Prediction of neuromotor outcome using Alberta Infant Motor Scale (AIMS) scores

    Sensitivity and specificity of AIMS scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The AIMS is a norm-referenced observational assessment with a minimum score of 0 and a maximum score of 58. Higher scores indicate better motor performance on the assessment.

    Measured: 6 months, 9 months, 1 year

  3. Prediction of neuromotor outcome using Hammersmith Infant Neurological Examination (HINE) scores

    Sensitivity and specificity of HINE scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The HINE is a neurological exam with a minimum score of 0 and a maximum score of 78. Higher scores indicate better performance on the assessment.

    Measured: 6 months, 9 months, 1 year

  4. Prediction of neuromotor outcome using Test of Infant Motor Performance (TIMP) scores

    Sensitivity and specificity of TIMP scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]).

    Measured: 1-2 weeks, 1 month, 3 months

  5. Clinical score estimation

    Error between true clinical test scores and scores estimated from sensor and video data, assessed at each remaining time-point.

    Measured: 1-2 weeks, 1 month, 9 months, 1 year, 2 years

  6. Prediction of neuromotor outcome at 2 years using sensor and video data from the remaining time-points

    Sensitivity and specificity of algorithm (trained on sensor and video data from the remaining time-points) to predict neuromotor outcome at 2 years (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])

    Measured: 1-2 weeks, 1 month, 9 months, 1 year, 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2018
  2. Study start29 Mar 2019
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03770832
Sponsor's protocol ID
SX04202018
Status last verified
Jan 2026
First submitted
6 Dec 2018
Last updated
21 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Motor Delay and Neurodevelopmental Disorders, run by Shirley Ryan AbilityLab at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Three month clinical score estimation (time frame: 3 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in